Polymorphism of the G protein β3 subunit gene influences the efficacy of sildenafil in patients with pulmonary hypertension

Internal Medicine

Volumn 53, Issue 4, 2014, Pages 291-297

  Sekine, Ayumi ^a   Tanabe, Nobuhiro ^a   Sugiura, Toshihiko ^a   Shigeta, Ayako ^a   Jujo, Takayuki ^a   Nishimura, Rintaro ^a   Sakao, Seiichiro ^a   Kasahara, Yasunori ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Chronic thromboembolic pulmonary hypertension; Pharmacogenomics; Polymorphism; Sildenafil

Indexed keywords

ADULT; AGED; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PURINES; RETROSPECTIVE STUDIES; SULFONES; TREATMENT OUTCOME; VASODILATION;

EID: 84893984859     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.0658     Document Type: Article

References (25)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
3. Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 183: 1605-1613, 2011.
4. Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3: 571-576, 2006.
5. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141: 702-710, 2011.
6. Ishida K, Masuda M, Tanabe N, Matsumiya G, Tatsumi K, Nakajima N. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 144: 321-326, 2012.
7. Tanabe N, Sugiura T, Jujo T, et al. Subpleural perfusion as a predictor for a poor surgical outcome in chronic thromboembolic pulmonary hypertension. Chest 141: 929-934, 2012.
8. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124: 1973-1981, 2011.
9. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 58: 629-631, 2003.
10. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140: 1274-1283, 2011.
11. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361: 1864-1871, 2009.
12. Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 134: 229-236, 2008.
13. Siffert W, Rosskopf D, Siffert G, et al. Association of a human Gprotein beta3 subunit variant with hypertension. Nat Genet 18: 45-48, 1998.
14. Fernandez-Real JM, Penarroja G, Richart C, et al. G protein beta3 gene variant, vascular function, and insulin sensitivity in type 2 diabetes. Hypertension 41: 124-129, 2003.
15. Baumgart D, Naber C, Haude M, et al. G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Circ Res 85: 965-969, 1999.
16. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37: 739-743, 2001.
17. Sperling H, Eisenhardt A, Virchow S, et al. Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. J Urol 169: 1048-1051, 2003.
18. Siffert W. Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy. Kidney Int (84) Suppl: S168-S171, 2003.
19. Torfgard K, Ahlner J, Axelsson KL. Relaxation of bovine mesenteric arteries by glyceryl trinitrate and other nitro-compounds: evidence for partly different mechanisms of action. Pharmacol Toxicol 67: 216-221, 1990.
20. Piatti PM, Monti LD, Zavaroni I, et al. Alterations in nitric oxide/ cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 85: 2416-2420, 2000.
21. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 19: 3068-3073, 2000.
22. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a Referral centre. Eur Respir J 39: 945-955, 2012.
23. Sugimura K, Fukumoto Y, Satoh K, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76: 485-488, 2012.
24. Sitbon O, Jaris X, Savale L, et al. Upfront triple combination therapy of I.V. epoprostenol with oral bosentan and sildenafil in idiopathic and heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 183: A5910, 2011.
25. Rubin LJ, Simmoneau G, Badesch D, et al. The study of risk in pulmonary arterial hypertension. Eur Respir Rev 21: 234-238, 2012.